Galvumet is a combination medication that belongs to the class of drugs known as antidiabetic agents. It combines vildagliptin and metformin for treating type 2 diabetes. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin is a biguanide.
Galvumet is a combination medication designed to manage type 2 diabetes mellitus.
It combines two active ingredients, vildagliptin and metformin, each representing a distinct class of antidiabetic agents.
Vildagliptin: Vildagliptin is classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor. DPP-4 inhibitors work by inhibiting the action of the enzyme DPP-4, which breaks down incretin hormones.
Incretins help regulate blood sugar levels by stimulating the release of insulin and reducing the production of glucose in the liver.
Metformin: Metformin belongs to the biguanide class of medications.
It primarily works by decreasing the amount of glucose produced by the liver and improving the body's response to insulin, thereby lowering blood sugar levels.
Metformin is often a first-line treatment for type 2 diabetes.
By combining these two agents, Galvumet addresses multiple aspects of glucose regulation.
Vildagliptin enhances insulin secretion in response to meals, while metformin reduces the amount of glucose produced by the liver and enhances insulin sensitivity in peripheral tissues like muscles.
It's essential for individuals prescribed Galvumet to follow their healthcare provider's guidance closely, including dosage instructions and monitoring of blood sugar levels.
Additionally, any concerns or potential side effects should be promptly discussed with a healthcare professional for appropriate management.
As with any medication, individual responses may vary, and healthcare providers consider the patient's overall health and specific medical history when prescribing Galvumet or alternative treatments.
Question
What class of drug is Galvumet?